Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)GlobeNewsWire • 06/12/24
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)GlobeNewsWire • 06/11/24
Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare ConferenceGlobeNewsWire • 06/04/24
Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)GlobeNewsWire • 05/30/24
Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare DiseaseGlobeNewsWire • 04/30/24
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate UpdateGlobeNewsWire • 04/25/24
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman SyndromeGlobeNewsWire • 04/12/24
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual MeetingGlobeNewsWire • 04/12/24
Compared to Estimates, Ultragenyx (RARE) Q4 Earnings: A Look at Key MetricsZacks Investment Research • 02/16/24
Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdateGlobeNewsWire • 02/15/24
What Analyst Projections for Key Metrics Reveal About Ultragenyx (RARE) Q4 EarningsZacks Investment Research • 02/12/24
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate UpdateGlobeNewsWire • 02/08/24
Ultragenyx (RARE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 02/08/24
Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)GlobeNewsWire • 02/06/24